REVERSAL BY A DIHYDROPYRIDINE DERIVATIVE OF NON-P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE IN ETOPOSIDE-RESISTANT HUMAN PROSTATIC-CANCER CELL-LINE

被引：19

作者：

TASAKI, Y

NAKAGAWA, M

OGATA, J

KIUE, A

TANIMURA, H

KUWANO, M

NOMURA, Y

机构：

[1] OITA MED UNIV,DEPT UROL & SURG,OITA 87955,JAPAN

[2] NIKKEN CHEM CO LTD,OMIYA RES LAB,OMIYA,SAITAMA,JAPAN

[3] KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 812,JAPAN

来源：

JOURNAL OF UROLOGY | 1995年 / 154卷 / 03期

关键词：

DIHYDROPYRIDINES; DRUG RESISTANCE; MULTIPLE; PROSTATIC NEOPLASMS;

D O I：

10.1016/S0022-5347(01)67033-2

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose: We have isolated etoposide-resistant prostatic cancer cell Lines, P/VP10 and P/VP20, to investigate the multidrug resistance (MDR) mechanism and to find MDR reversal agents. Materials and Methods: We examined expression of MDR-related genes and screened reversal agents of MDR in P/VP20 cells. Results: These cells demonstrated a non-P-glycoprotein (P-gp)-mediated MDR phenotype with overexpression of MDR-associated protein (MRP) mRNA due to MRP DNA amplification. A 1,4-dihydropyridine derivative, bis(4-pyridylmethyl)4-[2-(3-methyl-5,6-dihydro-1,4-dithiinyl)] -2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (NIK250), was found to overcome MDR in P/VP20 cells. Conclusions: NIK250 might be useful in reversing MDR, which often develops during chemotherapy of advanced or hormone-resistant prostatic cancer.

引用

页码：1210 / 1216

页数：7

共 20 条

[1]

Chen, Chin, Ueda, Clark, Pastan, Gottesman, Roninson, Internal duplication and homology with bacterial transport proteins in the mdr 1 (P-glycoprotein) gene from multidrug-resistant human cells, Cell, 47, (1986)

[2]

Gerlach, Endicott, Juranka, Henderson, Sarangi, Deuchars, Ling, Homology between P-glycoprotein and a bacterial hemolysin transport protein suggests a model for multidrug resistance, Nature, 324, (1986)

[3]

Danks, Yalowich, Beck, Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26), Cancer Res., 47, (1987)

[4]

Sullivan, Latham, Rowe, Ross, Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line, Biochemistry, 28, (1989)

[5]

Bugg, Danks, Beck, Suttle, Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemia cells selected for resistance to teniposide, Proc. Natl. Acad. Sci. U.S.A., 88, (1991)

[6]

Cole, Chanda, Dicke, Gerlach, Mirski, Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II, Cancer Res., 51, (1991)

[7]

Nakagawa, Schneider, Dixon, Horton, Kelley, Morrow, Cowan, Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells, Cancer Res., 52, (1992)

[8]

Schneider, Horton, Yang, Nakagawa, Cowan, Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance, Cancer Res., 54, (1994)

[9]

Cole, Bhardwaj, Gerlach, Machie, Grant, Almquist, Stewart, Kurz, Duncan, Deeley, Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line, Science, 258, (1992)

[10]

Kakehi, Kanamaru, Yoshida, Ohkubo, Nakanishi, Gottesman, Pastan, Measurement of multidrug-resistance messenger RNA in urogenital cancers: elevated expression in renal cell carcinomas associated with intrinsic drug resistance, J. Urol., 139, (1988)

← 1 2 →